Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis

J Comp Eff Res. 2018 Nov;7(11):1107-1123. doi: 10.2217/cer-2018-0075. Epub 2018 Sep 19.


Aim: A network meta-analysis using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity Index [PASI] and Psoriatic Arthritis Response Criteria [PsARC] response rates) at 12-16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab and ustekinumab.

Patients & methods: Trials were identified by systematic review. Separate networks were developed for the full-study populations, biologic-naive patients and biologic-experienced patients.

Results: In the full populations, secukinumab, adalimumab, golimumab and infliximab demonstrated the highest ACR response rates. Secukinumab and infliximab demonstrated the highest PASI response rates, and infliximab and etanercept demonstrated the highest PsARC response rates.

Conclusion: In the full populations, secukinumab demonstrated good efficacy across all outcomes. All treatments for active PsA included in this comprehensive network meta-analysis demonstrated superiority to placebo.

Keywords: ACR; PASI; PsARC; biologic therapy; network meta-analysis; psoriatic arthritis; secukinumab.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Adalimumab / therapeutic use
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Psoriatic / drug therapy*
  • Biological Products / therapeutic use*
  • Comparative Effectiveness Research
  • Etanercept / therapeutic use
  • Humans
  • Infliximab / therapeutic use
  • Network Meta-Analysis
  • Randomized Controlled Trials as Topic
  • Thalidomide / analogs & derivatives


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Thalidomide
  • golimumab
  • Infliximab
  • secukinumab
  • Adalimumab
  • Etanercept
  • apremilast